Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non–Small Cell Lung Cancer

Bairavi Shankar, Jiajia Zhang, Abdul Rafeh Naqash, +14

JAMA Oncology

Profiling Preexisting Antibodies in Patients Treated With Anti–PD-1 Therapy for Advanced Non–Small Cell Lung Cancer

Yukihiro Toi, Shunichi Sugawara, Jun Sugisaka, +14

JAMA Oncology

Association of Immune-Related Adverse Events with Clinical Benefit in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Nivolumab

Yukihiro Toi, Shunichi Sugawara, Yosuke Kawashima, +13

The Oncologist

Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With <i>EGFR</i> T790M–Mutated Non–Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor

Hiroaki Akamatsu, Yukihiro Toi, Hidetoshi Hayashi, +14

JAMA Oncology

Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort

Abdul Rafeh Naqash, Biagio Ricciuti, Dwight H. Owen, +15

Cancer Immunology Immunotherapy

Cancer EpidemiologyPooled Exploratory AnalysisMedicineCancer ManagementImmunology +6

Association Between Skin Reaction and Clinical Benefit in Patients Treated with Anti-Programmed Cell Death 1 Monotherapy for Advanced Non-Small Cell Lung Cancer

Mari Aso, Yukihiro Toi, Jun Sugisaka, +15

The Oncologist

Complete Atrioventricular Block Associated with Pembrolizumab-induced Acute Myocarditis: The Need for Close Cardiac Monitoring

Yumi Katsume, Tsuyoshi Isawa, Yukihiro Toi, +4

Internal Medicine

Heart FailurePathologyAcute Myocardial InfarctionImmune Checkpoint InhibitorsPembrolizumab-induced Acute Myocarditis +15

Nivolumab Retreatment in Non–Small Cell Lung Cancer Patients Who Responded to Prior Immune Checkpoint Inhibitors and Had ICI-Free Intervals (WJOG9616L)

Hiroaki Akamatsu, Shunsuke Teraoka, Shinkichi Takamori, +13

Clinical Cancer Research

Relationship between Programmed Cell Death Protein Ligand 1 Expression and Immune-related Adverse Events in Non-small-cell Lung Cancer Patients Treated with Pembrolizumab

Jun Sugisaka, Yukihiro Toi, Masataka Taguri, +15

JMA Journal

Incidence, Clinical Characteristics, and Predictors of Cardiovascular Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors

Tsuyoshi Isawa, Yukihiro Toi, Shunichi Sugawara, +2

The Oncologist